Gelsolin: A Comprehensive Pan-cancer Analysis of Potential Prognosis, Diagnostic, and Immune Biomarkers

Overview

Journal Front Genet

Date 2023 Apr 10

PMID 37035750

Authors

Yiyang Wang

Xiaojuan Bi

Zhiwen Luo

Haiyan Wang

Dilimulati Ismtula

Chenming Guo

Affiliations

Soon will be listed here.

Abstract

Gelsolin (GSN), a calcium-regulated actin-binding protein, is out of balance in various cancers. It can mediate cytoskeletal remodeling and regulate epithelial-mesenchymal conversion (EMT), but the studies on GSN function in pan-cancer are limited. We studied the transcription level, prognostic impact, diagnostic value, genetic, epigenetic modification, methylation level and immune significance of GSN in pan-cancer to fully comprehend the function of GSN in various malignancies based on multiple databases like The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Pan-cancer research showed that GSN was downregulated in most tumors and expressed differently in immunological and molecular subtypes of many cancers. GSN had varying impacts on the prognosis of various tumor types. However, all had moderate to high diagnostic efficiency, and serum GSN had good diagnostic value in breast cancer patients (AUC = 0.947). Moreover, GSN was a distinguishing prognosis factor for some specific cancer types. The GSN protein was hypophosphorylated, and its promoter was hypermethylated in most cancers. GSN was linked to the infiltration level of several immunity cells and was essential in anti-tumor immune cell infiltration. KEGG and GSEA analyses showed that GSN was vital in the functions and proteoglycans processes in cancer, chemokine signaling pathway and other immune-related pathways, DNA methylation and cell cycle. In conclusion, GSN possesses the ability to be a predictive, diagnostic, and immune indicator in pan-cancer.

Citing Articles

Integration of Single Cell and Bulk RNA-Sequencing Reveals Key Genes and Immune Cell Infiltration to Construct a Predictive Model and Identify Drug Targets in Endometriosis.

Zhang H, Fang Y, Luo D, Li Y J Inflamm Res. 2025; 18:2783-2804.

PMID: 40026309 PMC: 11871914. DOI: 10.2147/JIR.S497643.

Phenotypic rescue via mTOR inhibition in neuron-specific Pten knockout mice reveals AKT and mTORC1-site specific changes.

DAmore A, Sundberg M, Lin R, Lubbers E, Winden K, Yu L Mol Psychiatry. 2025; .

PMID: 39953287 DOI: 10.1038/s41380-025-02916-2.

Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA.

Du T, Yuan Y, Sun S, Gao Z, Li X BMC Womens Health. 2024; 24(1):674.

PMID: 39736579 PMC: 11687186. DOI: 10.1186/s12905-024-03486-1.

Prognostic model based on tumor stemness genes for triple-negative breast cancer.

Ouyang M, Gui Y, Li N, Zhao L Sci Rep. 2024; 14(1):30855.

PMID: 39730613 PMC: 11680876. DOI: 10.1038/s41598-024-81503-x.

Early Warning of Axillary Lymph Node Metastasis in Breast Cancer Patients Using Multi-Omics Signature: A Machine Learning-Based Retrospective Study.

Ke Z, Shen L, Shao J Int J Gen Med. 2024; 17:6101-6114.

PMID: 39687219 PMC: 11648545. DOI: 10.2147/IJGM.S499238.

References

Nag S, Ma Q, Wang H, Chumnarnsilpa S, Lee W, Larsson M . Ca2+ binding by domain 2 plays a critical role in the activation and stabilization of gelsolin. Proc Natl Acad Sci U S A. 2009; 106(33):13713-8. PMC: 2720848. DOI: 10.1073/pnas.0812374106. View

Filipovic A, Miller G, Bolen J . Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. Front Cell Dev Biol. 2020; 8:155. PMC: 7092703. DOI: 10.3389/fcell.2020.00155. View

Yuan X, Yu L, Li J, Xie G, Rong T, Zhang L . ATF3 suppresses metastasis of bladder cancer by regulating gelsolin-mediated remodeling of the actin cytoskeleton. Cancer Res. 2013; 73(12):3625-37. DOI: 10.1158/0008-5472.CAN-12-3879. View

Ben-David U, Amon A . Context is everything: aneuploidy in cancer. Nat Rev Genet. 2019; 21(1):44-62. DOI: 10.1038/s41576-019-0171-x. View

Huang C, Lee K, Tung S, Huang W, Teng C, Lee K . 2D-DIGE-MS Proteomics Approaches for Identification of Gelsolin and Peroxiredoxin 4 with Lymph Node Metastasis in Colorectal Cancer. Cancers (Basel). 2022; 14(13). PMC: 9265116. DOI: 10.3390/cancers14133189. View

Wu Y, Zheng J, Yan Y, Liu J, Zhou Y . Gelsolin Can Be a Prognostic Biomarker and Correlated with Immune Infiltrates in Gastric Cancer. Int J Gen Med. 2022; 15:927-936. PMC: 8803610. DOI: 10.2147/IJGM.S339940. View

Asare-Werehene M, Nakka K, Reunov A, Chiu C, Lee W, Abedini M . The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene. 2019; 39(7):1600-1616. PMC: 7018662. DOI: 10.1038/s41388-019-1087-9. View

Yang J, Wang C, Cai J, Chou C, Lin Y, Hung C . Identification of GSN and LAMC2 as Key Prognostic Genes of Bladder Cancer by Integrated Bioinformatics Analysis. Cancers (Basel). 2020; 12(7). PMC: 7408759. DOI: 10.3390/cancers12071809. View

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

10.

Kim J, Ha Y, Tak K, Roh S, Kwon Y, Kim C . Opposite functions of GSN and OAS2 on colorectal cancer metastasis, mediating perineural and lymphovascular invasion, respectively. PLoS One. 2018; 13(8):e0202856. PMC: 6110496. DOI: 10.1371/journal.pone.0202856. View

11.

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

12.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q . TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509-W514. PMC: 7319575. DOI: 10.1093/nar/gkaa407. View

13.

Li G, Arora P, Chen Y, McCulloch C, Liu P . Multifunctional roles of gelsolin in health and diseases. Med Res Rev. 2012; 32(5):999-1025. DOI: 10.1002/med.20231. View

14.

Shah A, Hartel G, Brown I, Winterford C, Na R, Le Cao K . Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus. Mol Cell Proteomics. 2018; 17(12):2324-2334. PMC: 6283291. DOI: 10.1074/mcp.RA118.000734. View

15.

Wang P, Abedini M, Yang L, Ding A, Figeys D, Chang J . Gelsolin regulates cisplatin sensitivity in human head-and-neck cancer. Int J Cancer. 2014; 135(12):2760-9. DOI: 10.1002/ijc.28928. View

16.

Liu X, Huang X, Ma J, Li L, Hu H, Feng J . 3'untranslated regions (3'UTR) of mRNA displays anticancer effects in non-small cell lung cancer (NSCLC) cells. Am J Cancer Res. 2021; 11(8):3857-3876. PMC: 8414377. View

17.

Hogg S, Beavis P, Dawson M, Johnstone R . Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov. 2020; 19(11):776-800. DOI: 10.1038/s41573-020-0077-5. View

18.

Shimasaki N, Jain A, Campana D . NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020; 19(3):200-218. DOI: 10.1038/s41573-019-0052-1. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Tang Z, Kang B, Li C, Chen T, Zhang Z . GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019; 47(W1):W556-W560. PMC: 6602440. DOI: 10.1093/nar/gkz430. View